Cargando…

Multicenter Analytical Validation of Aβ40 Immunoassays

BACKGROUND: Before implementation in clinical practice, biomarker assays need to be thoroughly analytically validated. There is currently a strong interest in implementation of the ratio of amyloid-β peptide 1-42 and 1-40 (Aβ42/Aβ40) in clinical routine. Therefore, in this study, we compared the ana...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Waalwijk van Doorn, Linda J. C., Kulic, Luka, Koel-Simmelink, Marleen J. A., Kuiperij, H. Bea, Versleijen, Alexandra A. M., Struyfs, Hanne, Twaalfhoven, Harry A. M., Fourier, Anthony, Engelborghs, Sebastiaan, Perret-Liaudet, Armand, Lehmann, Sylvain, Verbeek, Marcel M., Vanmechelen, Eugeen J. M., Teunissen, Charlotte E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497061/ https://www.ncbi.nlm.nih.gov/pubmed/28725210 http://dx.doi.org/10.3389/fneur.2017.00310

Ejemplares similares

A Practical Guide to Immunoassay Method Validation
por: Andreasson, Ulf, et al.
Publicado: (2015)

The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease
por: De Vos, Ann, et al.
Publicado: (2016)

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease
por: Dorey, Aline, et al.
Publicado: (2015)

TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies
por: Goossens, Joery, et al.
Publicado: (2015)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
por: Teunissen, Charlotte E., et al.
Publicado: (2018)

Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
por: Vanderstichele, Hugo Marcel, et al.
Publicado: (2019)

Bioinformatics tools and data resources for assay development of fluid protein biomarkers
por: Waury, Katharina, et al.
Publicado: (2022)

Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease
por: De Kort, Anna M., et al.
Publicado: (2021)

A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an example
por: Herbert, Megan K., et al.
Publicado: (2015)

Reduced Influence of apoE on Aβ43 Aggregation and Reduced Vascular Aβ43 Toxicity as Compared with Aβ40 and Aβ42
por: Jäkel, Lieke, et al.
Publicado: (2020)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
por: De Vos, Ann, et al.
Publicado: (2017)

Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease
por: Santaella, Anna, et al.
Publicado: (2020)

Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms
por: Santaella, Anna, et al.
Publicado: (2020)

Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
por: De Kort, Anna M., et al.
Publicado: (2021)

Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
por: De Kort, Anna M., et al.
Publicado: (2021)

MicroRNA-29a Is a Candidate Biomarker for Alzheimer’s Disease in Cell-Free Cerebrospinal Fluid
por: Müller, Mareike, et al.
Publicado: (2015)

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients
por: Bridel, Claire, et al.
Publicado: (2018)

Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood‐brain barrier
por: Biemans, Elisanne A.L.M., et al.
Publicado: (2016)

MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy
por: Marques, Tainá M., et al.
Publicado: (2016)

Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia
por: Das, Shreyasee, et al.
Publicado: (2023)

Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls
por: Marques, Tainá M., et al.
Publicado: (2018)

VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
por: Bridel, Claire, et al.
Publicado: (2017)

Cerebrospinal Fluid P-Tau(181P): Biomarker for Improved Differential Dementia Diagnosis
por: Struyfs, Hanne, et al.
Publicado: (2015)

Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis
por: Loonstra, Floor C., et al.
Publicado: (2022)

CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome
por: Khalil, M, et al.
Publicado: (2013)

CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders
por: Herbert, Megan K., et al.
Publicado: (2015)

Proteomic profiling of striatal tissue of a rat model of Parkinson's disease after implantation of collagen‐encapsulated human umbilical cord mesenchymal stem cells
por: Santaella, Anna, et al.
Publicado: (2020)

Potential sources of interference on Abeta immunoassays in biological samples
por: Vanderstichele, Hugo, et al.
Publicado: (2012)

P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
por: Wesenhagen, Kirsten E. J., et al.
Publicado: (2022)

Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer’s Disease
por: Niemantsverdriet, Ellis, et al.
Publicado: (2016)

Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach
por: Marques, Tainá M., et al.
Publicado: (2021)

Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays
por: del Campo, Marta, et al.
Publicado: (2015)

A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer’s Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration
por: Das, Shreyasee, et al.
Publicado: (2022)

Serum Contactin-1 in CIDP: A Cross-Sectional Study
por: Wieske, Luuk, et al.
Publicado: (2021)

Chasing the Effects of Pre-Analytical Confounders – A Multicenter Study on CSF-AD Biomarkers
por: Leitão, Maria João, et al.
Publicado: (2015)

Inhaled carbon monoxide protects time-dependently from loss of hypoxic pulmonary vasoconstriction in endotoxemic mice
por: Jahn, Nora, et al.
Publicado: (2015)

A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias
por: Bolsewig, Katharina, et al.
Publicado: (2022)

Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage
por: Jäkel, Lieke, et al.
Publicado: (2020)

Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
por: Chatterjee, Madhurima, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hb3kh2o02eq0f63g48g8lql8mi